Jaffer Khan

A clinical observation that I find more important than most longevity headlines: hormonal architecture is one of the most under-managed areas of medicine for adults over 40, and it is one of the most consequential. I see this every week in practice. Patients in their forties, fifties and sixties presenting with symptoms — fatigue, sleep disruption, cognitive slowing, loss of muscle mass, mood change, libido decline, recovery time after exertion — that they have been told are normal features of aging. Frequently they are not. They are reflections of a hormonal system that has shifted away from its optimal physiological range, and which can, with appropriate clinical judgement, be returned much closer to it. What an honest clinical position on hormonal optimisation looks like: → Diagnostics first. No protocol decision without a comprehensive baseline. Free and total testosterone, oestradiol, progesterone, DHEA, cortisol architecture, thyroid panel, IGF-1, SHBG, and a range of metabolic and inflammatory co-markers. Treating to symptom without proper baseline data is, in my view, indefensible. → The menopause transition is materially more consequential than mainstream medicine has historically treated it. The cardiovascular, cognitive and skeletal implications of estrogen and progesterone signalling extend well beyond the reproductive years. The clinical reckoning around menopausal hormone therapy is overdue, and is finally arriving. → Male hormonal decline deserves the same diagnostic seriousness. Testosterone optimisation in symptomatic men with documented deficiency is well-evidenced and clinically defensible. Wholesale supplementation in asymptomatic men with normal-range readings is something different, and the field needs to be honest about that distinction. → Hormonal optimisation is not a standalone intervention. It sits inside a wider protocol that includes metabolic health, sleep architecture, training stimulus, stress modulation and nutrition. Treated in isolation it is consistently disappointing. Treated as part of the wider physiology, it is consistently effective. Hormonal medicine, properly practised, is one of the most clinically rewarding domains. It also requires more clinical judgement than any other area I would name. The evidence base is real, but it is not formulaic. It will be a substantial conversation at Next Generation Medicine - Future of Longevity #hormones #health #aeonclinic #NGM2026 #Dubai

Conventional corporate wellness has been measuring the wrong things for two decades. Step counts. Annual screenings. Gym subsidies. Activity metrics that tell you almost nothing of clinical substance about a workforce's actual healthspan trajectory. The premise of conventional corporate wellness is largely reactive — detect early, manage chronic conditions, attempt to reduce absenteeism. These are legitimate aims. They are also, in my view, manifestly insufficient for the population most organisations are now trying to retain at the top of their performance curve. Longevity medicine asks a substantially different question: not how decline is managed, but how the period of optimal cognitive, metabolic, and physical function is extended. For senior leadership, the distinction matters considerably. Biological and chronological age are not synonymous. A 52-year-old can present with the metabolic and inflammatory profile of a 38-year-old, or a 67-year-old. The interventions & modifications that meaningfully shift that trajectory exist, are evidence-based, and are increasingly accessible. At The AEON Clinic, we have built a corporate longevity programme designed against this premise. Not wellness as a benefit. Wellness as performance infrastructure with measurable trajectory data. At Next Generation Medicine - Future of Longevity 2026 we are bringing senior corporate health leaders, People Directors and C-suite decision-makers into the conversation alongside the clinical faculty. The organisations that engage seriously with this now will be operating from a different baseline in five years. Does your organisation's wellness programme measure biological age or healthspan trajectory in any structured way? I would be interested to hear what you are doing. #CorporateWellness #ExecutiveHealth #LongevityMedicine #HRLeadership #BiologicalAge #AEONclinic

The establishment of the Dubai Longevity Authority marks a defining moment for the future of healthcare in our city. Dubai has never been content to follow global progress; it creates the infrastructure, ambition and standards that allow new industries to lead. This development reinforces a healthcare model focused not only on treating disease, but on extending healthspan, preserving performance and improving quality of life. At The AEON Clinic, we are proud to support this vision by translating advances in longevity science, precision diagnostics and regenerative medicine into responsible, personalised clinical care. Thank you to Gulf News for highlighting this important new chapter for Dubai and the wider healthcare sector. https://lnkd.in/ekU5ndhU #aeonclinic #dubai #longevity

At Next Generation Medicine - Future of Longevity I will sit on the Investor and Innovator Forum panel. A few notes on why this conversation is timely. When the 2026 edition was being structured, we took a deliberate decision: the investor conversation would not be a side track. It would close the opening day, in the same room as the clinical and translational science. The reasoning is straightforward. Longevity medicine has reached the point where the science and the capital must move together. The science has matured ahead of the infrastructure. The infrastructure now needs to catch up — clinics, diagnostics, regulatory frameworks, scalable delivery models. That is, at this stage, primarily a capital allocation question rather than a scientific one. If you operate in private equity, family office, or healthcare investment, this is a panel I would point you to. #longevity #dubai #aeonclinic #investor #uae #ngm2026

I am asked frequently what differentiates Next Generation Medicine - Future of Longevity Congress from others in this space. The honest answer is that it was designed against a different premise. Most congresses present the science. NGM 2026 is built to translate it into clinical and operational practice. The four-day programme spans around: → GLP-1 receptor agonists as longevity therapeutics; mTOR modulation; NAD+ metabolism → Epigenetic reprogramming — the current state, and the realistic translation horizon → Reproductive longevity → Stem cell protocols and the standards conversation around them → AI-driven digital twins and the ethics of autonomous clinical support → Regenerative ophthalmology — corneal reconstruction through to retinal gene editing → The Swiss Framework for longevity clinic governance → Investment trends, regulatory translation, and the policy environment The full programme is taking shape. More to follow. Which area is most relevant to your work? I am genuinely interested in where the appetite sits. #longevity #nextgenerationmedicine2026 #aeonclinic #dubai

Most people still misunderstand longevity medicine. It is not about chasing trends, isolated treatments, or the promise of living forever. It is about understanding the biological processes that determine how we age — inflammation, metabolic health, hormones, epigenetics, cellular function, recovery, cognition and resilience — and building a structured clinical pathway around that data. In this interview with Lightberg Magazine I speak about why ageing is biological before it is chronological, why diagnostics must come before treatment, and why regenerative medicine only works properly when the internal environment is addressed first. This is the direction medicine is moving in. Not reactive disease management. Proactive, personalised, measurable healthspan medicine. Thank you to The Lightberg for the feature: https://lnkd.in/dX2AwcsE #longevity #aeonclinic #dubai #atlantistheroyal #regenerativemedicine

Dubai is not positioning itself as a wellness destination. It is positioning itself as a longevity capital. The distinction matters. Wellness destinations attract visitors. Longevity capitals attract investment, clinical talent, infrastructure, and regulatory attention. They become the hubs around which an industry organises itself. The conditions in Dubai are increasingly aligned for the latter. The regulatory environment for advanced therapies — reflected in the work of the UAE Stem Cell Group, the Dubai Health Authority framework, and the engagement of government stakeholders in longevity policy — is developing with unusual seriousness and pace. The capital is following. GCC sovereign funds and family offices are now examining the healthspan economy as a structural investment thesis, across biotechnology, clinical infrastructure, diagnostics, and wellness-adjacent hospitality. It is part of why we located both The AEON Clinic and Next Generation Medicine - Future of Longevity Congress at Atlantis The Royal. Not for the venue alone, although it is exceptional but because the address itself is part of the signal. What we are building is intended to set a regional standard, and the location is part of how that standard is communicated. The question for serious investors and policymakers is not whether Dubai becomes a longevity capital. It is the rate at which it does, and which operators build the foundational infrastructure first. Do you see Dubai — or the wider GCC — as an emerging centre for longevity medicine and investment? Perspectives from across the region welcomed. #Dubai #LongevityCapital #GCCInvestment #HealthspanEconomy #RegenerativeMedicine #AEON #AtlantisTheRoyal

Three decades into a plastic and reconstructive surgical career, I have watched the discipline migrate quietly but decisively into regenerative territory. When I trained at St Bartholomew's and the Royal London in the late 1980s, the architecture of plastic surgery was largely structural. We restored form, we reconstructed defects, we rebuilt function after burns and trauma. The biology of healing was something we worked with — not something we modulated directly. What has changed, particularly over the past fifteen years, is the proximity of regenerative science to operative practice. Autologous fat grafting, used routinely now in breast and facial reconstruction, is fundamentally a stem cell procedure — adipose-derived progenitor cells migrate, differentiate and remodel host tissue. Platelet-rich plasma, exosome therapy, biostimulator-driven facial protocols, and the clinical use of growth factors in wound healing — all of these sit at the operative interface. It is not theoretical. It is the operating field a contemporary plastic surgeon now occupies. This is part of why building AEON was a clinically logical decision rather than a commercial one. The same biology that drives modern reconstructive practice — tissue regeneration, cellular signalling, modulation of inflammatory and remodelling pathways — is the biology that drives healthspan medicine. The difference is the question we are asking the biology to answer. In surgery, the question is: how do we restore. In longevity medicine, the question is: how do we delay the need for restoration in the first place. The two practices, in my view, are increasingly the same conversation. For surgical colleagues — where do you see the operative discipline most clearly converging with regenerative science in your own work? #PlasticSurgery #RegenerativeMedicine #ReconstructiveSurgery #FatGrafting #AestheticsInternational #AEON #ClinicalPractice

The longevity industry is not a niche. It is the largest addressable market in human history. Eight billion people age. The demand is permanent and universal. Research published in Nature Aging in 2023 — co-authored by Andrew Scott, David Sinclair (Harvard Medical School) and Martin Ellison — quantified the economic value of slowing aging. A one-year increase in US life expectancy delivered through a slowdown in aging is estimated to be worth approximately $38 trillion in net present value, with a ten-year increase valued at $367 trillion. Institutions are beginning to respond to figures of that magnitude. This is no longer speculative. The science has matured. The clinical infrastructure is being built. The regulatory frameworks are forming. What happens next is, in large part, a question of capital allocation — and which jurisdictions and operators are positioned to absorb it. At Next Generation Medicine - Future of Longevity 2026, 7–10 November at Atlantis the Royal, Dubai — we have dedicated an Investor and Innovator Forum to exactly this conversation. I will join that panel alongside several of the more rigorous financial minds working at this intersection. If you operate in private equity, family office, sovereign wealth or healthcare investment, this is a discussion worth being part of. Where do you see the most acute under-investment in the longevity economy at present? #LongevityEconomy #HealthspanInvestment #RegenerativeMedicine #FutureOfHealthcare #NGMCongress #PrivateEquity

An observation from the consulting room over the past three years: the most consequential change in clinical medicine at present is not a new therapeutic. It is the volume of data we now hold on the patient before they walk into the room. Continuous glucose monitors. Wearable cardiac and sleep monitoring. At-home biomarker panels. Advanced imaging. Multi-omic profiling. The tools now generate datasets per patient that, fifteen years ago, would have required a short hospital admission to assemble. The data is no longer the constraint. The constraint is the clinical capacity to interpret it well. Three observations from practising in this environment day-to-day: → The patient is now an informed participant in a way that materially alters the consultation. They arrive with months of physiological data, sometimes years of it. The clinician's task has shifted from gathering information to making clinical sense of what they have already gathered. That is a different skill, and not one that medical training has fully caught up with. → AI-supported pattern recognition is now genuinely useful at the level of the individual case. Not as a replacement for clinical judgement, but as augmentation. Subtle metabolic drift, sleep architecture changes, heart rate variability trends — these are signals an attentive clinician can read with the right tooling, and miss without it. The clinics that integrate this well will deliver materially better outcomes than those that do not. → The medico-legal and ethical questions are not yet resolved. Continuous data creates continuous responsibility. What does duty of care look like when a wearable flags an arrhythmia at 2am? The frameworks are still being written. This is the operational reality of what people term Medicine 3.0. It is not a futurist concept. It is a clinical environment that already exists, and the gap between clinics that have built around it and clinics that have not is widening. At Next Generation Medicine - Future of Longevity 2026, Philippe GERWILL leads a session on this directly, and a separate panel that addresses intelligence at the bedside & how AI redefines clinical decision making and future of longevity care. If you are integrating continuous-data tools clinically — what has demonstrably changed in your decision-making, and what has not? #ContinuousMonitoring #ClinicalAI #LongevityMedicine #FutureOfMedicine #NGMCongress #AEON

One of the challenges facing longevity medicine today is not a lack of innovation—it is the need for greater academic rigour, clinical governance, and educational standards. That is why I am pleased to announce Prof. Dominik Thor as Program Co-Chair of Next Generation Medicine - Future of Longevity 2026. As President of the Geneva College of Longevity Science, Professor of Pharmacy, and a recognised leader in longevity and pharmaceutical sciences, Prof. Thor has dedicated much of his career to advancing the scientific and academic foundations of our field. His work spans research, biotechnology, medical product development, and higher education, with contributions that have resulted in multiple patented innovations in cell regeneration, skin rejuvenation, and hair restoration. More importantly, he has been instrumental in fostering collaboration between academia, industry, and healthcare institutions to elevate the standards of longevity medicine globally. As longevity medicine moves from emerging discipline to mainstream healthcare, the role of education, accreditation, and evidence-based practice becomes increasingly important. Through GCLS, Prof. Thor is helping shape the frameworks that will support the future credibility and adoption of longevity medicine worldwide. I look forward to sharing the stage with him at NGM Congress 2026 and to the important discussions ahead on how we collectively build the clinic of the future. #NGMCongress2026 #LongevityMedicine #GCLS #ClinicalGovernance #DominikThor #AEON

An observation from clinical practice: chronological age tells you progressively less about a patient as the science of biological age matures. The maturation of epigenetic clocks over the past decade is, in my view, one of the most consequential developments in the way we approach individualised medicine. The genome is largely fixed. The epigenome — the system of chemical modifications that determines which genes are expressed — is dynamic, and changes throughout life in response to environment, lifestyle, illness, and intervention. Horvath's clock, GrimAge, DunedinPACE and their successors quantify these changes and produce biological age estimates that correlate strongly with morbidity and mortality outcomes. The clinical implication is significant. A patient's biological age can sit measurably above or below their chronological age — and that gap is not fixed. Targeted intervention, ranging from structured lifestyle modification through to specific therapeutics, can shift the trajectory. Epigenetic reprogramming is one of the most closely watched areas of longevity research at present. The work of Altos Labs and academic groups exploring whether partial reprogramming can genuinely reverse cellular aging sits at the frontier — and the clinical translation timeline remains uncertain. It will be a substantial conversation at Next Generation Medicine - Future of Longevity Congress. Discriminating between where the science genuinely is and where the public conversation has overrun it remains, I think, one of the more important capacities a clinician working in this space needs to develop. 💬 If you are using epigenetic age testing in clinical practice — I would be interested in how the field is settling on protocols around it. #Epigenetics #BiologicalAge #EpigeneticClocks #LongevityMedicine #RegenerativeMedicine #AEON #NGMCongress

Next Generation Medicine- Future of Longevity Congress is coming back. Those of you who attended or followed our previous congress will know what we have been building toward. The Congress returns this November — and we have moved it to a venue that reflects the scale of what this field deserves. We will be hosting at Atlantis The Royal, Dubai. For those unfamiliar: it is one of the most iconic properties in the world, and it is where The AEON Clinic operates. The congress and the clinic, under one roof. That is not a coincidence, it is a statement of intent. The dates are 7–10 November 2026. More to come on speakers, programme, and how to be part of it. But I wanted this community to hear it first. The science has moved fast. The clinical standards have matured. The conversation we are about to have in Dubai will reflect that. #NextGenerationMedicine #LongevityMedicine #RegenerativeMedicine #AEON #AtlantisTheRoyal #Dubai #NGMCongress 💬 Were you at a previous edition? What would you want to see on the programme this time?

Last year, we hosted our first ever Next Generation Medicine Masterclass, powered by The AEON Clinic. The response was clear: clinicians and players within the longevity ecosystem want less hype and more substance, what works, for whom, and how to implement it safely. This year, we are back bigger—expanding from a masterclass into a full Congress in Dubai. The purpose remains the same: translate science into clinical protocols, with an uncompromising focus on evidence, outcomes, and real-world application. What the Congress will cover: Longevity and preventive medicine: standards, monitoring, and long-term outcomes Regenerative medicine: patient selection, safety, and measurable endpoints Diagnostics, biomarkers, and interpretation frameworks Clinical protocols you can take back to your practice The operational and regulatory realities of delivering next-generation care at scale The longevity economy and investment landscape: where capital is flowing, what models are scaling, and what “investable” longevity looks like in practice 📍 Atlantis The Palm, Dubai, UAE 📅 April 13th - 16th, 2026 🔗 Register Here: https://lnkd.in/dj8BrX_D If you attended last year’s masterclass—thank you. If you couldn’t, this is the moment to join us. #AEONClinic #NextGenerationMedicine #LongevityEconomy #HealthcareInnovation #RegenerativeMedicine #PreventiveMedicine #PrecisionMedicine #Dubai

Honoured to speak at the Vogue Business Summit on “The Future of Appearance.” Our discussion focused on how longevity has become the new luxury in beauty, with consumers increasingly looking beyond quick fixes toward long-term, regenerative approaches. We explored the evolving landscape, from invasive treatments to innovations that prioritise restoration, prevention, and overall well-being. Beauty is no longer just about appearance, it's about sustaining vitality, confidence, and health over time. The future is regenerative, intentional, and deeply personal. Thank you to the Vogue Business team and my fellow panelists for an inspiring and forward-thinking conversation. The AEON Clinic #VogueBusinessSummit #FutureOfAppearance #LongevityInBeauty #RegenerativeBeauty #BeautyInnovation #NewLuxury

We are interested in employing a DHA Licensed Laser and Beauty therapist with some years of experience in Dubai, Preferably with own client base. If you are interested in joining our team please send your CV to info@aesthetics.ae

Looking forward to participating as Moderator of the Smart Aging Panel at UAE Genetic Diseases Association Arabian Business The AEON Clinic #wellness #dubai #uae #aeonclinic

A great & collaborative meeting with P7 Medicine Medical Centre from Germany, associated with the University of Cologne and European Prevention Center. P7MEDICINE: INTERNATIONAL CENTER FOR PERSONALIZED MEDICINE LTD specializes in personalized medicine and stem cell therapies. Professor Nayernia Professor Hescheler Professor Nixdorff Dr. Vahdani Saba Habibollah (MD, PhD, MSc Genetics, MSc Healthcare Leadership) #longevity #stemcelltherapy #dubai #aeonclinic

How The AEON Clinic's regenerative medicine is shaping a new health standard for the future of #longevity #aeonclinic #dubai #wellness #healthcare #clinic

We are interested in employing a DHA Licensed Laser and Beauty therapist with some years of experience in Dubai, Preferably with own client base. If you are interested in joining our team please send your CV to info@aesthetics.ae